United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - mexiletine hydrochloride (unii: 606d60is38) (mexiletine - unii:1u511hhv4z) - capsule - 150 mg - mexiletine hydrochloride capsules are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. mexiletine hydrochloride is contraindicated in the presence of cardiogenic shock or pre-existing second- or third-degree av block (if no pacemaker is present). acute liver injury: in post-marketing experience abnormal liver function tests have been reported, some in the first few weeks of therapy with mexiletine hydrochloride. most of these hav

United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - meperidine hydrochloride (unii: n8e7f7q170) (meperidine - unii:9e338qe28f) - tablet - 50 mg - meperidine hydrochloride tablets are indicated for the relief of moderate to severe pain. meperidine hydrochloride tablets are contraindicated in patients with hypersensitivity to meperidine. meperidine is contraindicated in patients who are receiving monoamine oxidase (mao) inhibitors or those who have recently received such agents. therapeutic doses of meperidine have occasionally precipitated unpredictable, severe, and occasionally fatal reactions in patients who have received such agents within 14 days. the mechanism of these reactions is unclear, but may be related to a preexisting hyperphenylalaninemia. some have been characterized by coma, severe respiratory depression, cyanosis, and hypotension, and have resembled the syndrome of acute narcotic overdose. in other reactions the predominant manifestations have been hyperexcitability, convulsions, tachycardia, hyperpyrexia, and hypertension. although it is not known that other narcotics are free of the risk of such reactions, virtually all of the reporte

United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - triamterene (unii: ws821z52lq) (triamterene - unii:ws821z52lq), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - tablet - 37.5 mg - this fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. - triamterene and hydrochlorothiazide tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. triamterene and hydrochlorothiazide tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. - triamterene and hydrochlorothiazide is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of cardiac arrhythmias, etc.). triamterene and hydrochlorothiazide is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of

United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - bisoprolol fumarate (unii: ur59kn573l) (bisoprolol - unii:y41js2nl6u), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - tablet, film coated - 2.5 mg - bisoprolol and hydrochlorothiazide is indicated in the management of hypertension. bisoprolol and hydrochlorothiazide is contraindicated in patients in cardiogenic shock, overt cardiac failure (see warnings), second or third degree av block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs.

United States - English - NLM (National Library of Medicine)

watson laboratories inc. - diltiazem hydrochloride (unii: olh94387te) (diltiazem - unii:ee92bbp03h) - tablet, extended release - 120 mg - diltiazem hydrochloride extended release tablets are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive medications. diltiazem hydrochloride extended release tablets are indicated for the management of chronic stable angina. diltiazem is contraindicated in (1) patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker, (2) patients with second- or third-degree av block except in the presence of a functioning ventricular pacemaker, (3) patients with hypotension (less than 90 mm hg systolic), (4) patients who have demonstrated hypersensitivity to the drug, and (5) patients with acute myocardial infarction and pulmonary congestion documented by x-ray on admission.

United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - chlordiazepoxide hydrochloride (unii: mfm6k1xwdk) (chlordiazepoxide - unii:6rz6xez3cr) - capsule - 5 mg - chlordiazepoxide hci capsules are indicated for the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the effectiveness of chlordiazepoxide in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. the physician should periodically reassess the usefulness of the drug for the individual patient. chlordiazepoxide hci capsules are contraindicated in patients with known hypersensitivity to the drug. chlordiazepoxide hci capsules are classified by the drug enforcement administration as a schedule iv controlled substance. withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt discontinuance of chlordiazep

United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - clonazepam (unii: 5pe9fde8gb) (clonazepam - unii:5pe9fde8gb) - tablet - 0.5 mg - seizure disorders: clonazepam is useful alone or as an adjunct in the treatment of the lennox-gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. in patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam may be useful. in some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within three months of administration. in some cases, dosage adjustment may re-establish efficacy. panic disorder: clonazepam is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in dsm-iv. panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. the efficacy of clonazepam was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the dsm-lllr category of panic diso

United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - tablet, film coated, extended release - 100 mg - morphine sulfate extended-release tablets are a controlled release oral morphine formulation indicated for the relief of moderate to severe pain. they are intended for use in patients who require repeated dosing with potent opioid analgesics over periods of more than a few days. morphine sulfate extended-release is contraindicated in patients with known hypersensitivity to the drug, in patients with respiratory depression in the absence of resuscitative equipment, and in patients with acute or severe bronchial asthma. morphine sulfate extended-release is contraindicated in any patient who has or is suspected of having a paralytic ileus. opioid analgesics may cause psychological and physical dependence (see warnings). physical dependence results in withdrawal symptoms in patients who abruptly discontinue the drug or may be precipitated through the administration of drugs with narcotic antagonist activity, e.g., naloxone or mixed agonist/antagonist analgesics (pentazocine, etc.; see also overdosage). physical d

United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494) - injection - promethazine hcl injection is indicated for the following conditions: - amelioration of allergic reactions to blood or plasma. amelioration of allergic reactions to blood or plasma. - in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. - for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. - for sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. for sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. - active treatment of motion sickness. active treatment of motion sickness. - prevention and control of nausea and vomiting

United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - tablet - ranitidine tablets are indicated in: - short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. - the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). the treatment of pathological h